Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Finished Goods (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Finished Goods data on record, last reported at $3.5 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 7.06% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $3.5 million, up 7.06%, while the annual FY2025 figure was $3.5 million, 7.06% up from the prior year.
  • Finished Goods reached $3.5 million in Q4 2025 per MIRM's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Finished Goods topped out at $11.3 million in Q3 2023 and bottomed at $87000.0 in Q4 2021.
  • Average Finished Goods over 5 years is $3.5 million, with a median of $3.3 million recorded in 2024.
  • Peak YoY movement for Finished Goods: surged 6200.0% in 2023, then crashed 65.22% in 2024.
  • A 5-year view of Finished Goods shows it stood at $87000.0 in 2021, then skyrocketed by 145.98% to $214000.0 in 2022, then surged by 4311.68% to $9.4 million in 2023, then plummeted by 65.22% to $3.3 million in 2024, then rose by 7.06% to $3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $3.5 million in Q4 2025, $2.8 million in Q3 2025, and $3.7 million in Q2 2025.